Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

Pomerantz LLP is investigating claims on behalf of investors of  Geron Corporation ("Geron" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581 ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company’s net product revenue for RYTELO reached $47.5 million in ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...